Regeneron Pharmaceuticals, Inc.

Regeneran Pharmaceuticals, Inc.

Janelle Waite

Andrew J Murphy

George D Yancopoulos

Dimitris Skokos

Aynur Hermann

Erica Ullman

Eric L Smith

Lauric Haber

Eric B Smith

Kara Olson

Alison Crawford

Joyce Wei

The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing PSMA, such as prostate tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.

Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof

Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof

The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16, such as ovarian tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.

Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof

The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.

Bispecific anti-CD28 &#xd7; anti-CD22 antibodies and uses thereof

Growing community of inventors

Bronx, NY, United States of America

Janelle Waite